GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, researchers in Italy have found.

Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world ...

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days.

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule ACCESS Newswire - Wed Jun 11, 4:05AM CDT ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...

Lexaria Bioscience (LEXX) announced that human study GLP-1-H25-5 which compared oral capsules of DehydraTECH-liraglutide to injected Saxenda-branded liraglutide has been completed with partial ...